Third National Surgical Consensus Conference of the Italian Association of Breast Surgeons (ANISC) on Management after Neoadjuvant Chemotherapy: the difficulty in reaching a Consensus

D. Terribile | L. Giaccherini | A. Polistena | S. Zanotti | L. Costarelli | C. Zamagni | I. Meattini | A. Curcio | A. Sgarella | C. Garcia-Etienne | Antonio Rizzo | M. Roncella | M. Serra | F. Mascioni | M. Nunzi | A. Sibilio | G. Meneghini | D. Morichetti | S. Burlizzi | E. Manna | M. Ghilli | S. Stani | Giuseppe Accardo | Elena Santini | P. R. Raviele | V. L. Troilo | C. Magni | S. Papi | M. Amabile | L. Seriau | J. Foglietta | C. Soatti | M. Milanesio | S. Cappelli | M. Foroni | G. Apicella | A. Pellegrini | C. Tessa | Grazia Sorbo | D. Fenocchio | Anna Pensa | L. Santurro | A. Baldissera | A. Thodas | Francesco Caruso | Lucia Angelini | F. Combi | I. Puccica | A. D. Andrulli | P. A. Sanna | P. Vignutelli | A. Leone | Luciano Curella | M. A. Botticella | T. Mastropietro | Giuliano D'Onghia | Felicia Giacobbe | M. G. Galasso | E. Z. Meli | M. Pinta | M. Gasperoni | M. I. Gattuso | M. Natale | Anna Chiara Camilletti | L. Balzarotti | M. Santoni | Lauretta Massaza | Anna Trapani | Jacopo Cumbo | Renato Reitano | Lorenzo Livi | Oreste D Gentilini | L. Del Mastro | Donatella Santini | Elia Guadagno | Emma Firpo | Olindo Custodero | Secondo Folli | Massimo Busani | Alfonso Schiavone | Fabrizio Ventimiglia | M. Taffurelli | Isabella Castellano | Daniela Bernardi | Mauro Minelli | Lucio Fortunato | Virginia Ceccarossi | Luigi Marino Cosentino | Giuseppe Amaturo | Paola Bondioli | A. D. Luca | Antonia Gala | Antonia Lozupone | Massimo Grassi | Valeria Santoro | Ada Ala | Elisabetta Carfora | Giada Pozzi | Alba Pellegrini | Sara Frati | Giuliana Giuliani | Anna Maria Conte | Monica Minischetti | Mariacarla Valli | Andrea Lippi | A. Ravarino | Adele Calzolaro | Anna Neri | Luciano Carli | Laura Mambelli | Agnese Prisco | Enrico Di Marzio | Annalisa Venturini | M. Sicignano | Stefano Chiavilli | Roberto Gennari | Marica Melina | M. L. D'aponte | Alessandro Germano | Giulia Baldoni | Alessio Bonanni | Salvatore Tondo | Vania Marchetti | Michela Cassinotti | S. Grendele | F. Spolveri | Francesco Pellegrini | A. Cremonini | Damiano De Tullio | C. Aristei | Silvia Nesi | D. Gentile | V. Galimberti | P. Panizza | Jose Andres Diaz Nanez | Lorenza Marino | Alice Marzetti | Antonia De Rosa | Filippo Borri | Annamaria Ruggieri | Asioli Silvia | Francesco Patrone | Enza Palma | Simona Cima | Marina Minafra | Sara Giorgini | Simona Grossi | Barbara Campanella | Rossella Fante | S. Teggi | Alessandro Sanguinetti | Marzia Pieroni | Elisa Villa | Patrizia Querzoli | Alessandra Perfetti | Davide Ciriotto | Giovanna Guida | Elisa Canova | Maria Lunardi | Nicola Rocco | M. Minelli | G. Giuliani

[1]  G. Purkalne,et al.  Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience , 2023, Hereditary Cancer in Clinical Practice.

[2]  E. Mittendorf,et al.  Preoperative Immunotherapy Combined with Chemotherapy for Triple-Negative Breast Cancer: Perspective on the KEYNOTE-522 Study , 2023, Annals of Surgical Oncology.

[3]  M. Knauer,et al.  Tailored axillary surgery – A novel concept for clinically node positive breast cancer , 2023, Breast.

[4]  M. Ellis,et al.  Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. , 2023, The Lancet. Oncology.

[5]  G. Bousquet,et al.  HER2 Amplification Level Predicts Pathological Complete Response in the Neoadjuvant Setting of HER2-Overexpressing Breast Cancer: A Meta-Analysis and Systematic Review , 2023, International journal of molecular sciences.

[6]  B. Rehman,et al.  Is complete pathological response truly a complete response in breast cancer? , 2023, JPMA. The Journal of the Pakistan Medical Association.

[7]  L. Costarelli,et al.  Nipple-Sparing Mastectomy After Neoadjuvant Chemotherapy: Definitive Results with a Long-Term Follow-Up Evaluation , 2023, Annals of Surgical Oncology.

[8]  J. Qiu,et al.  Predicting Axillary Response in Hormone Receptor-Positive Breast Cancer after Neoadjuvant Chemotherapy Using Real-World Data , 2022, Journal of oncology.

[9]  F. Puglisi,et al.  Chemotherapy in patients with early breast cancer: clinical overview and management of long-term side effects , 2022, Expert opinion on drug safety.

[10]  C. Perou,et al.  HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial , 2022, EBioMedicine.

[11]  M. Piccart,et al.  Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Yang Yu,et al.  Clinical, Pathological Complete Response, and Prognosis Characteristics of HER2-Low Breast Cancer in the Neoadjuvant Chemotherapy Setting: A Retrospective Analysis , 2022, Annals of Surgical Oncology.

[13]  L. Boersma,et al.  De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5-year follow-up results of a Dutch, prospective, registry study. , 2022, The Lancet. Oncology.

[14]  M. Morrow,et al.  Is Nodal Clipping Beneficial for Node-Positive Breast Cancer Patients Receiving Neoadjuvant Chemotherapy? , 2022, Annals of Surgical Oncology.

[15]  J. Kulka,et al.  Editorial: Guidelines From the Central-Eastern European Professional Consensus Statement on Breast Cancer , 2022, Pathology & Oncology Research.

[16]  Lingeng Lu,et al.  Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies? , 2022, Current oncology.

[17]  T. Kühn,et al.  Axillary surgery after neoadjuvant therapy in initially node-positive breast cancer: international EUBREAST survey. , 2022, The British journal of surgery.

[18]  I. Bolengo,et al.  Contrast-Enhanced Mammography Versus MRI in the Evaluation of Neoadjuvant Therapy Response in Patients With Breast Cancer: A Prospective Study. , 2022, AJR. American journal of roentgenology.

[19]  A. Cusmai,et al.  KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer. , 2022, Future oncology.

[20]  A. Sapino,et al.  Pathological examination of breast cancer samples before and after neoadjuvant therapy: recommendations from the Italian Group for the Study of Breast Pathology - Italian Society of Pathology (GIPaM-SIAPeC) , 2022, Pathologica.

[21]  P. Okunieff,et al.  Evaluating Regional Nodal Irradiation Allocation and Association with Oncologic Outcomes in NSABP B-18, B-27, B-40, and B-41. , 2022, International journal of radiation oncology, biology, physics.

[22]  P. Mcgale,et al.  Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality , 2022, Cancer treatment reviews.

[23]  P. Fasching,et al.  Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. , 2022, The New England journal of medicine.

[24]  C. Perou,et al.  Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer , 2022, EBioMedicine.

[25]  R. Jagsi,et al.  Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research , 2022, Breast Cancer Research and Treatment.

[26]  L. Boersma,et al.  European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. , 2022, The Lancet. Oncology.

[27]  L. Esserman,et al.  Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients , 2021, The Lancet. Oncology.

[28]  T. King,et al.  De-escalating axillary surgery in early-stage breast cancer , 2021, Breast.

[29]  M. Lux,et al.  Axillary Staging after Neoadjuvant Chemotherapy for Initially Node-Positive Breast Carcinoma in Germany , 2021, Geburtshilfe und Frauenheilkunde.

[30]  U. Wazir,et al.  De-Escalation of Breast Cancer Surgery Following Neoadjuvant Systemic Therapy. , 2021, European journal of breast health.

[31]  E. Senkus,et al.  De-escalation of axillary irradiation for early breast cancer - Has the time come? , 2021, Cancer treatment reviews.

[32]  D. Berry,et al.  Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. , 2021, JAMA oncology.

[33]  S. Möller,et al.  Impact of neoadjuvant chemotherapy on surgical complications in breast cancer: A systematic review and meta-analysis. , 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[34]  R. Gelber,et al.  Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. , 2021, The New England journal of medicine.

[35]  E. Rutgers,et al.  First Surgical National Consensus Conference of the Italian Breast Surgeons association (ANISC) on breast cancer management in neoadjuvant setting: Results and summary. , 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[36]  R. Bartsch.  ESMO 2020: highlights in breast cancer , 2021, memo - Magazine of European Medical Oncology.

[37]  C. Geyer,et al.  Adjuvant T-DM1 versus Trastuzumab in Patients with Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer: Subgroup Analyses from KATHERINE. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  B. Wang,et al.  The prognostic significance of TILs as a biomarker in triple-negative breast cancer: what is the role of TILs in TME of TNBC? , 2021, European review for medical and pharmacological sciences.

[39]  E. Provenzano.  Neoadjuvant Chemotherapy for Breast Cancer: Moving Beyond Pathological Complete Response in the Molecular Age. , 2021, Acta medica academica.

[40]  D. Murawa,et al.  Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA Study , 2021, Cancers.

[41]  C. Geyer,et al.  Abstract OT-03-01: Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05) , 2021 .

[42]  S. Kümmel,et al.  A systematic review and meta-analysis on the effect of neoadjuvant chemotherapy on complications following immediate breast reconstruction , 2020, Breast.

[43]  A. Glass,et al.  Avoiding Axillary Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy in Breast Cancer: Rationale for the Prospective, Multicentric EUBREAST-01 Trial , 2020, Cancers.

[44]  P. Neven,et al.  Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  A. Schneeweiss,et al.  Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer , 2020, Cancer.

[46]  T. Iwamoto,et al.  Biomarkers of neoadjuvant/adjuvant chemotherapy for breast cancer. , 2020, Chinese clinical oncology.

[47]  C. Kuhl,et al.  The requirements of a specialist breast centre , 2020, Breast.

[48]  P. Fasching,et al.  Pembrolizumab for Early Triple-Negative Breast Cancer. , 2020, The New England journal of medicine.

[49]  T. Shien,et al.  Adjuvant and neoadjuvant therapy for breast cancer. , 2020, Japanese journal of clinical oncology.

[50]  P. Bruzzi,et al.  NEONOD 2: Rationale and design of a multicenter non-inferiority trial to assess the effect of axillary surgery omission on the outcome of breast cancer patients presenting only micrometastasis in the sentinel lymph node after neoadjuvant chemotherapy , 2019, Contemporary clinical trials communications.

[51]  F. Alongi,et al.  Preoperative radiotherapy: A paradigm shift in the treatment of breast cancer? A review of literature. , 2019, Critical reviews in oncology/hematology.

[52]  S. Johnston,et al.  Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for treatment of ER-positive metastatic breast cancer. , 2019, Future oncology.

[53]  F. Sardanelli,et al.  Technique, protocols and adverse reactions for contrast-enhanced spectral mammography (CESM): a systematic review , 2019, Insights into Imaging.

[54]  F. Cardoso,et al.  Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  R. Mann,et al.  Breast MRI: State of the Art. , 2019, Radiology.

[56]  B. Laviolle,et al.  Predictive factors associated with involved margins in breast cancer treated with neoadjuvant chemotherapy followed by breast-conserving therapy. , 2019, Journal of gynecology obstetrics and human reproduction.

[57]  S. MacDonald,et al.  In Regard to Stecklein et al. , 2019, International journal of radiation oncology, biology, physics.

[58]  M. V. Vrancken Peeters,et al.  Breast conserving therapy after neoadjuvant chemotherapy; data from the Dutch Breast Cancer Audit. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[59]  R. Pratesi,et al.  Contrast-Enhanced Mammography (CEM) for Detecting Residual Disease after Neoadjuvant Chemotherapy: A Comparison with Breast Magnetic Resonance Imaging (MRI) , 2018, BioMed research international.

[60]  Diane D. Liu,et al.  Long-Term Impact of Regional Nodal Irradiation in Patients With Node-Positive Breast Cancer Treated With Neoadjuvant Systemic Therapy. , 2018, International journal of radiation oncology, biology, physics.

[61]  B. Patel,et al.  ASO Author Reflections: Role of Contrast-Enhanced Spectral Mammography in the Assessment of Residual Breast Cancer After Neoadjuvant Systemic Therapy , 2018, Annals of Surgical Oncology.

[62]  J. Boughey,et al.  The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB) , 2018, Annals of surgery.

[63]  P. Raina,et al.  Protocol for a Delphi consensus exercise to identify a core set of criteria for selecting health related outcome measures (HROM) to be used in primary health care , 2018, BMC Family Practice.

[64]  N. Biglia,et al.  Neoadjuvant systemic treatment for breast cancer in Italy: The Italian Society of Surgical Oncology (SICO) Breast Oncoteam survey. , 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[65]  Luca Braglia,et al.  Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging , 2017, Breast Cancer Research.

[66]  Xiao-nan Zhang,et al.  Neoadjuvant chemotherapy followed by surgery versus upfront surgery in non-metastatic non-small cell lung cancer: systematic review and meta-analysis of randomized controlled trials , 2017, Oncotarget.

[67]  L. Rubinstein,et al.  CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data , 2017, npj Breast Cancer.

[68]  A. Amini,et al.  The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[69]  M. Morrow,et al.  Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy , 2015, Nature Reviews Clinical Oncology.

[70]  R. Dinniwell,et al.  A Canadian national expert consensus on neoadjuvant therapy for breast cancer: linking practice to evidence and beyond. , 2014, Current oncology.

[71]  C. Grubbs,et al.  Effect of Withania somnifera root extract on spontaneous estrogen receptor-negative mammary cancer in MMTV/Neu mice. , 2014, Anticancer research.

[72]  J. Bogaerts,et al.  Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. , 2014, The Lancet. Oncology.

[73]  S. Mclaughlin,et al.  Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. , 2013, JAMA.

[74]  A. Goldhirsch,et al.  Best management of locally advanced inoperable breast cancer , 2013, EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.].

[75]  Les Irwig,et al.  Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. , 2013, Journal of the National Cancer Institute.

[76]  Stewart J Anderson,et al.  Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  T. Julian,et al.  Avoiding Mastectomy: Accelerated Partial Breast Irradiation for Breast Cancer Patients with Pacemakers or Defibrillators , 2011, Annals of Surgical Oncology.

[78]  Hon J. Yu,et al.  Residual Breast Cancer Diagnosed by MRI in Patients Receiving Neoadjuvant Chemotherapy with and Without Bevacizumab , 2009, Annals of Surgical Oncology.

[79]  S. Paik,et al.  Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  Christos Hatzis,et al.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  J. A. van der Hage,et al.  Neoadjuvant chemotherapy for operable breast cancer , 2007, The British journal of surgery.

[82]  Daniel Vanel,et al.  BIRADS classification in mammography. , 2007, European journal of radiology.

[83]  G. Hortobagyi,et al.  Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. , 2005, International journal of radiation oncology, biology, physics.

[84]  L. Brunereau,et al.  Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[85]  Serge Muller,et al.  Development of contrast digital mammography. , 2002, Medical physics.

[86]  B. Fisher,et al.  Preoperative (neoadjuvant) chemotherapy in patients with breast cancer. , 2001, Seminars in oncology.

[87]  G. Hortobagyi,et al.  Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.